Powerful House Democrats demand documents from Biogen about coordination with FDA on new Alzheimer’s drug

WASHINGTON — Two powerful House Democrats on Monday demanded documents from Biogen about the approval process, marketing, and pricing of its controversial new Alzheimer’s drug.

The letter is the latest move in a congressional investigation into Aduhelm’s approval and pricing spearheaded by House Committee on Oversight and Reform Chair Carolyn Maloney (D-N.Y.) and Energy and Commerce Chair Frank Pallone (D-N.J.). The request prominently references a STAT investigation that revealed Biogen had an off-the-books meeting with a prominent FDA regulator ahead of the drug’s unprecedented approval, and that the back-channel relationship between the two started earlier and was far more extensive than disclosed.

Read the rest…

Powerful House Democrats demand documents from Biogen about coordination with FDA on new Alzheimer’s drug

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top